

Press release  
April 16, 2008  
Kungsbacka, Sweden

## Proposal concerning members of the Board

### Supplement to the notice of the Annual General Meeting to be held on April 29, 2008

Vitrolife's election committee has in the notice to attend the Annual General Meeting on March 28, 2008 proposed that the members of the Board shall be five or six in number, without any deputies, and that the Board shall consist of the following members: Patrik Tigerschiöld (re-election), Madeleine Olsson-Eriksson (re-election), Semmy Rülff (re-election), Fredrik Mattsson (re-election) and Maris Hartmanis (new election). A presentation of Maris Hartmanis was made in the notice to attend the Annual General Meeting.

The election committee proposes Tord Lendau as the sixth member of the Board. Tord Lendau was born in 1957 and is today managing director of product area MedTech within Sandvik. Tord has previously been the CEO of Artimplant AB and he has also worked in senior positions in, for example, Noster Systems AB and Medtronic/Synectics. Today he is also a member of the Board for Nasdaq-listed ArthroCare, Inc. Tord Lendau does not own any shares in Vitrolife.

The company has been informed that shareholders representing approximately 38 percent of the shares and votes in the company support the proposal of the election committee.

April 16, 2008  
Kungsbacka, Sweden

The Board

#### Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.  
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

---

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.

---

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452.  
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

The information in this press release is such as that which Vitrolife is required to publish in accordance with the Securities Exchange and Clearing Operations Act.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.